CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology
April 22 2019 - 8:15AM
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of infectious and inflammatory
disease, today announced publication online of a pre-clinical data
abstract at the upcoming annual meeting of the American Society of
Clinical Oncology (ASCO), a major educational and scientific event
in oncology being held in Chicago, IL on May 31 through June 4,
2019.
The abstract, entitled "Effective targeted
antitumor activity of the antimicrobial agent taurolidine against
relapsed/refractory neuroblastoma: Cytotoxicity, target modulation,
and tumor xenograft studies", reviews a pre-clinical study in a
mouse model of neuroblastoma led by Dr. Aru Narendran, Professor of
Pediatrics, Oncology, Biochemistry and Molecular Biology, Cumming
School of Medicine, University of Calgary. ASCO will release
abstracts online on May 15, 2019.
About CorMedix
CorMedix Inc. is a biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of infectious and inflammatory
diseases. The Company is focused on developing its lead product
Neutrolin®, a novel, non-antibiotic antimicrobial solution designed
to prevent costly and dangerous bloodstream infections associated
with the use of central venous catheters, currently in Phase 3
development for patients undergoing chronic hemodialysis. Such
infections cost the U.S. healthcare system approximately $6 billion
annually and contribute significantly to increased morbidity and
mortality. Neutrolin has FDA Fast Track status and is designated as
a Qualified Infectious Disease Product, which provides the
potential for priority review of a marketing application by
FDA and allows for 5 additional years of QIDP market exclusivity in
the event of U.S. approval. Neutrolin is already marketed as a CE
Marked product in Europe and other territories. In parallel,
CorMedix is leveraging its taurolidine technology to develop a
pipeline of antimicrobial medical devices, with active programs in
surgical sutures and meshes, and topical hydrogels. The company is
also working with top-tier researchers to develop taurolidine-based
therapies for rare pediatric cancers. For more information,
visit: www.cormedix.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding
management’s expectations, beliefs, goals, plans or CorMedix’s
prospects, future financial position, financing plans, future
revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially
from projections or estimates due to a variety of important
factors, including: relying on preclinical results that may not be
indicative of success in clinical trials and might not be
replicated in any subsequent studies or trials; the risks and
uncertainties associated with research for additional uses for
taurolidine; risks relating to the effect of the recently-effected
reverse stock split on the Company’s stock price and its overall
market capitalization; the resources needed to terminate the Phase
3 trial and the costs and time needed to submit a new drug
application to the FDA; the risks and uncertainties associated with
CorMedix’s ability to manage its limited cash resources and the
impact on current, planned or future research, including the
continued development of Neutrolin;obtaining additional financing
to support CorMedix’s research and development and clinical
activities and operations; risks related to obtaining FDA approval
of the new drug application for Neutrolin; and the ability to
retain and hire necessary personnel to staff our operations
appropriately. These and other risks are described in greater
detail in CorMedix’s filings with the SEC, copies of which are
available free of charge at the SEC’s website at www.sec.gov or
upon request from CorMedix. CorMedix may not actually achieve the
goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements.
CorMedix assumes no obligation and does not intend to update these
forward-looking statements, except as required by law.
Investor Contact:Dan
FerryManaging DirectorLifeSci Advisors617-535-7746
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Apr 2024 to May 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From May 2023 to May 2024